Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.

Decitabine (5-aza-2'-deoxycytidine), an inhibitor of DNA methyltransferases, has a wide range of anti-metabolic and anti-cancer activities. Decitabine also induces cell cycle arrest at G2/M phase and apoptosis in human cancer cells. However, the cellular and molecular mechanisms of this cell cycle arrest are poorly understood. In the present study, we investigated the roles of the tumor suppressor p53 and the cyclin-dependent kinase (Cdk) inhibitor p21 following decitabine-induced G2/M arrest in human cancer cells. DNA flow cytometric analyses indicated that decitabine induced a G2/M arrest in AGS gastric and A549 lung carcinoma cell lines, which have wild type p53. Western blot analyses using whole cell lysates from AGS cells demonstrated that decitabine treatment did not change the steady-state level of Cdks and Cdk inhibitor p27, but it partially inhibited expression of cyclin A, cyclin B1, and Cdc25C proteins. However, similar results were found using the A549 cell line, where decitabine induced a dramatic up-regulation of both p53 and p21 expression, and the increased levels of p21 were associated with increased binding of p21 with Cdks, cyclin A, and cyclin B1. Knockdown of p53 by small interfering RNA (siRNA) markedly abolished p53 induction by decitabine in AGS cells, yet p53 siRNA had no attenuating effect on p21 induction. In addition, depletion of p21 expression with siRNA, but not p53, significantly attenuated decitabine-induced G2/M arrest. We also observed that decitabine strongly induced G2/M arrest associated with p21 induction in both p53 allele-null (-/-) HCT116 and wild type p53 (+/+) HCT116 cell lines. Therefore, our data indicated that p21 plays a crucial role in decitabine-induced G2/M arrest and operates in a p53-independent manner.

[1]  M. Esteller.  Epigenetic gene silencing in cancer: the DNA hypermethylome. , 2007, Human molecular genetics.

[2]  B. F. Vaniushin,et al.  [DNA methylation and epigenetics]. , 2006, Genetika.

[3]  M. Garrett,et al.  Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. , 2005, Current opinion in pharmacology.

[4]  S. Srivastava,et al.  Sulforaphane-induced G2/M Phase Cell Cycle Arrest Involves Checkpoint Kinase 2-mediated Phosphorylation of Cell Division Cycle 25C* , 2004, Journal of Biological Chemistry.

[5]  W. Gerald,et al.  A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies , 2006, PLoS medicine.

[6]  Yupo Ma,et al.  p150(Sal2) is a p53-independent regulator of p21(WAF1/CIP). , 2004, Molecular and cellular biology.

[7]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Yupo Ma,et al.  p150Sal2 Is a p53-Independent Regulator of p21WAF1/CIP , 2004, Molecular and Cellular Biology.

[9]  J. Minna,et al.  DNA methylation in health, disease, and cancer. , 2007, Current molecular medicine.

[10]  S. Hirohashi,et al.  5-Aza-2′-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis , 2004, Clinical & Experimental Metastasis.

[11]  R. Legerski,et al.  Artemis Links ATM to G2/M Checkpoint Recovery via Regulation of Cdk1-Cyclin B , 2007, Molecular and Cellular Biology.

[12]  Jing-Gung Chung,et al.  Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle. , 2006, Anticancer research.

[13]  A. Moon,et al.  HER2 induces expression of leptin in human breast epithelial cells , 2012, BMB reports.

[14]  J. Issa,et al.  Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia , 2003, Cancer.

[15]  M. Szyf.  DNA Methylation and Demethylation as Targets for Anticancer Therapy , 2005, Biochemistry (Moscow).

[16]  P. Kaldis,et al.  Established and novel Cdk/cyclin complexes regulating the cell cycle and development. , 2011, Results and problems in cell differentiation.

[17]  F. Lyko,et al.  DNA Methyltransferase Inhibitors for Cancer Therapy , 2007, Cancer journal.

[18]  P. Jagodziński,et al.  5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[19]  Jin Choul Chai,et al.  Genome-scale DNA methylation pattern profiling of human bone marrow mesenchymal stem cells in long-term culture , 2012, Experimental & Molecular Medicine.

[20]  A. Fusco,et al.  5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. , 1984, Blood.

[21]  B. Ducommun,et al.  Cell cycle control by the CDC25 phosphatases. , 2008, Anti-cancer agents in medicinal chemistry.

[22]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[23]  Vaidehi Jobanputra,et al.  The A-type cyclins and the meiotic cell cycle in mammalian male germ cells. , 2004, International journal of andrology.

[24]  M. Caudill,et al.  DNA methylation, genomic silencing, and links to nutrition and cancer. , 2005, Nutrition reviews.

[25]  H. Huynh,et al.  2‐Chloroethyl‐3‐sarcosinamide‐1‐nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53‐dependent and p53‐independent pathways , 2004, Cancer.

[26]  C. Plass,et al.  5-Aza-2′-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation* , 2004, Journal of Biological Chemistry.

[27]  Rolf Lewensohn,et al.  The role of p53 in treatment responses of lung cancer. , 2005, Biochemical and biophysical research communications.

[28]  A. Senderowicz,et al.  Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. , 2005, Cancer research.

[29]  E. Schmitt,et al.  DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis , 2007, Journal of Zhejiang University SCIENCE B.

[30]  P. Jagodziński,et al.  The role of mammalian DNA methyltransferases in the regulation of gene expression. , 2005, Cellular & molecular biology letters.

[31]  W. El-Deiry,et al.  Regulation of programmed cell death by the p53 pathway. , 2008, Advances in experimental medicine and biology.

[32]  Steven F Dowdy,et al.  Cip/Kip proteins: more than just CDKs inhibitors. , 2004, Genes & development.

[33]  J. Issa,et al.  Decitabine--bedside to bench. , 2007, Critical reviews in oncology/hematology.

[34]  Hui Wang,et al.  Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms , 2002, Molecular medicine.

[35]  W. El-Deiry,et al.  Clinical implication of p53 mutation in lung cancer , 2003, Molecular biotechnology.

[36]  Guillermo Garcia-Manero,et al.  Evolution of decitabine development , 2008, Cancer.